The non-qualified stock options, set to vest over four years, align with long-term employment incentives, thus promoting stability and continuity within the company. Notably, the options' exercise price will correspond with the stock's closing price on the grant date, which minimizes dilution for existing shareholders while fostering alignment of employee interests with those of investors. As the pharmaceutical sector often experiences volatility based on pipeline developments and regulatory approvals, every effort to ensure employee engagement and talent retention can be viewed as a contributing factor to Viridian's potential upside. Additionally, Viridian's active involvement in pivotal clinical trials for therapies targeting thyroid eye disease (TED) further enhances its market position. Success in these trials can significantly bolster the company's valuation and attract further investment. Analysts should consider the progress of the THRIVE and REVEAL studies in their forecasts.